FPIN’s Clinical Inquiries

Sunscreen Use for Skin Cancer Prevention

PATRICIA BOUKNIGHT, MD, and ANDREW BOWLING, MD†, Spartanburg Family Medicine Residency Program, Spartanburg, South Carolina
FRAN E. KOVACH, MLIS, Southern Illinois University School of Medicine, Springfield, Illinois

Clinical Inquiries provides answers to questions submitted by practicing family physicians to the Family Physicians Inquiries Network (FPIN). Members of the network select questions based on their relevance to family medicine. Answers are drawn from an approved set of evidence-based resources and undergo peer review. The strength of recommendations and the level of evidence for individual studies are rated using criteria developed by the Evidence-Based Medicine Working Group (http://www.cebm.net/?o=1025).

The complete database of evidence-based questions and answers is copyrighted by FPIN. If interested in submitting questions or writing answers for this series, go to http://www.fpin.org or e-mail: questions@fpin.org.

A collection of FPIN’s Clinical Inquiries published in AFP is available at http://www.aafp.org/afp/fpin.

Clinical Question
Does sunscreen use prevent skin cancer?

Evidence-Based Answer
Daily sunscreen use reduces the incidence of squamous cell carcinoma but not the incidence of basal cell carcinoma. (Strength of Recommendation [SOR]: B, based on a single randomized controlled trial with less than 13 years of follow-up). It is unclear whether there are longer-term effects. There is no consistent, conclusive evidence that sunscreen use prevents melanoma. (SOR: C, meta-analysis of case-control studies).

Evidence Summary

SQUAMOUS CELL CARCINOMA
In a randomized controlled trial, 1,621 participants in Nambour, Australia, were randomized to one of four treatment groups. Of the two groups assigned to daily sunscreen use, one group (n = 404) applied sun protection factor (SPF) 15 sunscreen to the head, neck, arms, and hands, and received daily oral beta carotene supplementation. The second group (n = 408) was assigned to sunscreen application plus an oral placebo. Of the two groups not assigned to daily sunscreen use, one group (n = 416) received daily oral beta carotene supplementation, and the other group (n = 393) received daily oral placebo. Participants who were not in the daily sunscreen groups were allowed discretionary use of sunscreen.

Over 4.5 years, persons in the daily sunscreen groups had a decreased incidence of squamous cell tumors at the sites of sunscreen application compared with those in the no daily sunscreen groups (28 tumors in 22 persons versus 46 tumors in 25 persons; rate ratio [RR] = 0.61; 95% confidence interval [CI], 0.37 to 0.98; number needed to treat = 140). Each group included persons of all skin types, with more than 50 percent of persons in each group having fair skin and 20 percent reporting that they “always burn.” An intention-to-treat analysis of 1,383 participants eight years after completion of the initial randomized controlled trial demonstrated a prolonged protective effect, with a 35 percent lower incidence of squamous cell carcinoma in the daily sunscreen groups (RR = 0.65; 95% CI, 0.43 to 0.98; number needed to treat = 2.8).

BASAL CELL CARCINOMA
In the Nambour study, the incidence of basal cell carcinoma in the daily sunscreen groups compared with the no daily sunscreen groups was not statistically significant after 4.5 years (153 tumors in 65 persons versus 146 tumors in 63 persons; RR = 1.05; 95% CI, 0.82 to 1.34). In the eight-year follow-up study, there was no statistically significant decrease in the incidence of basal cell carcinoma (RR = 0.75; 95% CI, 0.49 to 1.14). In an additional multifailure survival analysis, none of the three analysis models found a significant difference in the risk of subsequent basal cell carcinoma.

MELANOMA
A meta-analysis of 11 case-control studies involving 9,067 patients evaluated the effect of sunscreen use on the incidence of melanoma. Results were heterogeneous and included study data from population-based and hospital-based sources. The analysis did not find an altered rate of melanoma with sunscreen use (combined RR = 1.11; 95% CI, 0.37 to 3.32). A review of 18 case-control studies involving 1,383 participants eight years after completion of the initial randomized controlled trial demonstrated a prolonged protective effect, with a 35 percent lower incidence of squamous cell carcinoma in the daily sunscreen groups (RR = 0.65; 95% CI, 0.43 to 0.98; number needed to treat = 2.8).

Downloaded from the American Family Physician Web site at www.aafp.org/afp. Copyright © 2010 American Academy of Family Physicians. For the private, noncommercial use of one individual user of the Web site. All other rights reserved. Contact copyrights@aafp.org for copyright questions and/or permission requests.
studies examining sunscreen use in patients with melanoma found no significant association between melanoma and sunscreen use after controlling for skin sensitivity.\textsuperscript{5}

**Recommendations from Others**

The American Academy of Dermatology recommends year-round application of broad-spectrum sunscreen with SPF 30 or higher to all areas of the body exposed to the sun.\textsuperscript{6}

\[†—Deceased.\]

**EDITOR'S NOTE:** Dr. Bowling graduated from the University of South Carolina School of Medicine in Columbia, and completed his residency at the Spartanburg (S.C.) Family Medicine Residency Program. Dr. Bowling passed away in February 2010. He was in private practice in the Spartanburg community at the time of his death.

Copyright Family Physicians Inquiries Network. Used with permission.

Address correspondence to Patricia Bouknight, MD, at pbouknight@srhs.com. Reprints are not available from the authors.

Author disclosure: Nothing to disclose.

**REFERENCES**